Objective To examine whether there is an association between bile acids and coagulation factors in children with chronic liver disease.
Introduction
Most coagulation factors are synthesized in the liver and the levels of several procoagulant and anticoagulant proteins are often reduced in advanced liver disease [1] . Prothrombin time (PT) reported according to the international normalized ratio (INR) system, factor V (FV), and FVII are used as markers of hepatocellular function and prognosis in liver disease [2, 3] . INR is included in the King's College criteria for fulminant liver failure [4] . INR is also included in the model of end-stage liver disease (MELD) score and in the pediatric end-stage liver disease (PELD) score [5] . The latter scoring systems are used for liver allocation in the USA [6, 7] . INR includes FII, FVII, FX, fibrinogen, and FV when analyzed according to the Quick method, which is used in most Western countries. In the Nordic countries, however, the Owren method is used, which only measures FII, FVII, and FX [8] .
Increased levels of procoagulant proteins including fibrinogen and the coagulation factors II, FVII, and FX as well as the anticoagulant protein antithrombin have been described in the subgroups of adult patients with primary biliary cirrhosis, primary sclerosing cholangitis, and common duct stone [9] [10] [11] . These potentially confounding effects are overlooked when coagulation factors and INR are used as prognostic markers. Whether these effects are related to the current degree of cholestasis is not clear and the significance of this finding in pediatric liver disease is unknown.
The primary aim of this study was to examine whether there is an association between the levels of bile acids and the levels of coagulation factors in children with chronic liver disease (clinical study). The secondary aim was to investigate whether increased levels of bile acids could influence the measurement of coagulation factor levels (in-vitro study).
Patients and methods

Clinical study
Forty-five patients (age 2.8 months-18.8 years) with chronic liver disease and no previous liver transplant were included in this cross-sectional observational study at our tertiary center for pediatric hepatology at Karolinska University Hospital. The charts were reviewed and data on the following parameters were collected on a single occasion: age, sex, weight, height, diagnosis, treatment with vitamin K, steroids, or ursodeoxycholic acid. In addition, information on plasma concentrations of FII, FV, FVII, FIX and FX, PT, hemoglobin, platelet count, aspartate aminotransferase, alanine aminotransferase, bilirubin, alkaline phosphatase, g-glutamyltranspeptidase, albumin, total fasting serum bile acids (FSBAs), and cholinesterase was collected.
The data were compared with the outcome after 6 months and 5 years in terms of death or liver transplantation. Episodes of bleeding or thrombosis, verified with ultrasonography or computed tomography, within 6 months were documented.
The study was approved by the local ethics committee in accordance with the Helsinki Declaration of 1975. Informed consent was obtained from the parents or from the patients themselves if they were older than 18 years of age.
The plasma samples were collected prospectively and analyzed during the time period 1996-1999 at the Coagulation Unit, Department of Clinical Chemistry, Karolinska University Hospital. FV and FIX were analyzed using one-step clotting assays. The activators were neoplastin (Diagnostica Stago, Paris, France) and actin (Dade Behring, Marburg, Germany) for the FV and FIX assays, respectively. The instruments used were MLA 9000C (Medical Laboratory Automation Inc., Mount Vernon, New York, USA) and, from November 1997, Sysmex CA-6000 (Sysmex, Kobe, Japan). The change in instruments from MLA 9000C to Sysmex CA-6000, 1997, did not affect the results. The reference ranges were unchanged. FII, FVII, and FX were analyzed using chromogenic methods on the instrument Cobas Mira (Roche Diagnostics, Basel, Switzerland). The reagents used were staphylocoagulase 2000 CNTSE (Diagnostica Stago), human activator placenta thromboplastin (Chromogenix AB, Mölndal, Sweden), and Russell's viper venom (Chromogenix AB) for the FII, FVII, and FX assays, respectively [12] [13] [14] . PT was analyzed according to Owren and expressed as PT% (Stago Prothrombin Complex Assay, Diagnostica Stago). The results were recalculated as INR according to the formula INR = (1/PT% + 0.018)/0.028 [8] .
The FSBA levels were determined using the colorimetric enzymatic method (enzybile). The reagents were from Nycomed (Oslo, Norway) and the spectrophotometer was an LKB 7400 (Beckman Coulter, Fullerton, California, USA) [15] . All other laboratory tests were carried out according to hospital routine.
The PELD score was calculated as 0.480 Â log e (bilirubin mg/dl) + 1.857 Â log e (INR) -0.687 Â log e (albumin g/dl) + 0.436 if <1 years + 0.667 if there was growth failure (< 2 SD) Â 10 [5, 7] .
The patients were divided into two groups: those with FSBA concentrations below and above 200 mmol/l, respectively. We chose this cut-off level to be able to evaluate the patients with the most severe condition and with the highest probability for evaluation as liver transplant candidates.
In-vitro study
The bile acids taurocholic and glycocholic acids were chosen in this in-vitro study as these are found most abundantly in human plasma. In a previous study carried out by Bajwa and Hanahan [16] , these bile acids have been shown to stimulate one-stage clotting assays of prothrombin and FX when added at very high concentrations (equivalent to serum bile acid levels of 2000 mmol/l).
In the present study, the concentrations used were aimed to stay close to the physiologic ones, to examine whether FSBA could influence the results of clinical importance of the coagulation factor analyses. Sodium salts of taurocholic acid or glycocholic acid were dissolved in citrated pooled normal plasma with HEPES buffer (Cryocheck; PrecisionBioLogic Inc., Dartmouth, Nova Scotia, Canada) to generate two parallel series with increasing concentrations of serum bile acids. The resulting concentration of bile acids was determined according to the enzymatic colorimetric method application on a Modular P Analytics Automate (Roche Diagnostics). FII, FV, FVII, and FX were analyzed in the different bile acid dilutions with constant coagulation factor concentrations, according to a one-step clotting assay, as in the study carried out by Bajwa and Hanahan. [16] The analyses were carried out with the activator Thromborel S (Dade Behring) on a BCS instrument (Dade Behring). The chromogenic methods that were used for FII, FVII, and FX in the clinical study could not be investigated in this in-vitro study as they have been replaced by the clotting assays above, at our laboratory. The reference ranges remained unchanged despite the change in methods. PTwas analyzed according to Owren and expressed as INR (Stago Prothrombin Complex Assay; Diagnostica Stago), as in the clinical study.
Statistical analysis Clinical study
All results were entered into the statistics software Statistica, release 7 (StatSoft Scandinavia, Uppsala, Sweden). The characteristics of children with FSBA below and above 200 mmol/l were compared using Mann-Whitney's test, as the distributions were skewed. Correlation coefficients between FSBA and coagulation parameters were obtained using Spearman's rank correlation. A P value of less than 0.05 was considered statistically significant.
In-vitro study
The coefficients of variation (CV) for the coagulation factors, INR, and albumin in the samples with either 
Results
Clinical study
The demographic characteristics, liver function status, treatment, and clinical course for all the patients studied are shown in Table 1 . The various diagnoses in each group are shown in Table 2 . Figures 1 and 2 show the results of the coagulation tests. Some data were lacking for four of the patients with FSBA above 200 mmol/l: FII (two patients), FV (one patient), FVII (two patients), FIX (one patient), and FX (one patient).
In children with FSBA above 200 mmol/l, a significant positive correlation was found between FSBA and FV, FVII, and PT (r s = 0.80, P = 0.0031; r s = 0.72, P = 0.018; and r s = 0.60, P = 0.041, Figs 1 and 2). Positive but nonsignificant correlations were observed between FSBA and FII, FIX, and FX ( Fig. 1 ). There was a significant negative correlation between FSBA and INR (r s = -0.58, P = 0.048; Fig. 2 ).
Conversely, the group with FSBA below 200 mmol/l showed a significant negative correlation between FSBA and FVII and FIX (r s = -0.41, P = 0.017 and r s = -0.41, P = 0.0018; Fig. 1 ) and a positive correlation between FSBA and INR, albeit not significant (r s = 0.18, P = 0.32; Fig. 2 ). Negative nonsignificant correlations were found between FSBA and FII, FV, FX, and PT (Figs 1 and 2) .
Vitamin K treatment was more common in the high bile acid group compared with the low bile acid group. However, our study involved no interventions and all patients with an INR above 1.3 were routinely prescribed vitamin K1, except one, who had INR 1.64 and a bile acid level of 28 mmol/l. When the correlation analyses were carried out again without this patient, the results remained consistent. Vitamin K was administered orally to all except one patient, who received intravenous treatment. The latter patient was included in the high bile acid group.
The patients represented a fairly wide age span, and the two FSBA groups differed significantly in age. Reference ranges for the various coagulation factors and INR differ between different age groups [17] . In the age range less than 1 year, in which the reference ranges differ most from those in adults, our study included only four patients. One of them had FSBA below 200 mmol/l and the other three had FSBA above 200 mmol/l. Our main finding that patients in the high bile acid group had unexpectedly high levels of coagulation factors is unlikely to be explained by the fact that there were more patients younger than 1 year of age in this group, as infants that young usually have low levels of these coagulation factors. When the correlations between FSBA and coagulation parameters were recalculated without the children younger than 1 year of age, all significances remained unchanged, except for the correlation between FSBA and INR in the high FSBA group, and this correlation coefficient remained negative (r s = -0.64, P = 0.06).
There was no significant correlation between FSBA and albumin in the high FSBA group (r s = -0.04, P = 0.90), but in the low FSBA group, there was a significant negative correlation (r s = -0.5, P = 0.003; Fig. 1 ).
Twenty-five percent of the patients with FSBA above 200 mmol/l died or received transplants because of liver failure, within 6 months, versus 3% in the group with FSBA below 200 mmol/l (P = 0.025). Bleeding episodes in the gastrointestinal tract or nose were documented in four patients in the high bile acid group versus three in the low bile acid group. Two patients (one with low and one with high FSBA) had severe gastrointestinal bleeding episodes that necessitated blood transfusions and intensive care. The patient with high FSBA developed a concomitant portal vein thrombosis, verified by ultrasonography. Of all the patients studied, 50% of those with FVII less than 0.5 U/ml and 60% of those with INR more than 1.3 had bleeding symptoms. The PELD score was higher in the high FSBA group (although not significantly higher) and was strongly influenced by the INR. When the PELD scores were recalculated without INR, the difference between the groups became statistically significant (P = 0.017).
In-vitro study
The addition of increasing amounts of taurocholic or glycocholic acid to normal plasma (resulting in final serum bile acid concentrations between 3.6 and 467 mmol/l) did not result in higher levels of FII, FV, FVII, FX, or albumin, or in lower INR. The CV were between 0 and 5% in this study. For comparison, the method has a CV of 2-11% in routine clinical use.
Discussion
Our study found apparently higher levels of coagulation factors and lower INR in the patients with severely elevated FSBA than in those with lower FSBA. However, patients with FSBA above 200 mmol/l had a significantly worse outcome within 6 months. In other words, coagulation factors V and VII, PT, and INR do not seem to be accurate prognostic markers when the levels of FSBA are above 200 mmol/l.
The PELD score is expected to increase with progressing liver disease. In our study, however, the PELD score was not significantly higher in patients with high FSBA despite a worse condition, compared with those with low FSBA, unless INR was excluded from the equation. Thus, the INR component of the PELD equation may result in a disproportionately low PELD score in these patients.
Our classification of patients was based entirely on the actual level of FSBA and not on the underlying diagnoses, as the degree of cholestasis can vary with time and the half-life of the coagulation factors is comparatively short. For example, all three patients with progressive familial intrahepatic cholestasis were included in the group with FSBA below 200 mmol/l. All three of these patients had undergone a bile diversion several years earlier and had no clinical or biochemical signs of cholestasis at the time of the study; their FSBA was normal [18] . It has been found that levels between 10 and 100 mmol/l do not differentiate between hepatocellular and cholestatic liver damage [19] . We chose the serum fasting concentration of bile acids higher than 200 mmol/l to ensure that patients with the highest levels of bile acids were selected. Such high levels cannot be explained by treatment with ursodeoxycholic acid [20] .
Increased levels of bile acids did not influence the measurement of coagulation factor levels in our in-vitro study, although we used the same bile acids and the same method as Bajwa and Hanahan [16] . However, in the Bajwa and Hanahan study, serum bile acid levels equivalent to 2000 mmol/l were used. In our in-vitro study, the final serum bile acid concentrations were within the same range as in the samples from patients in our clinical study, reflecting a more physiologic situation. PT was analyzed using the same method in both the in-vitro and the clinical study and no interaction with bile acids was found.
Adult patients with primary biliary cirrhosis and primary sclerosing cholangitis are reported to have a more functional coagulation system (i.e. lower risk of bleeding and less need for transfusions during orthotopic liver transplantation) compared with patients with other cirrhotic states [10] . Hypercoagulability has been detected by thrombelastography in these two specific patient groups [21] . Among the causes of hypercoagulability that have been described in primary biliary cirrhosis and primary sclerosing cholangitis are changes related to inflammation with elevation in tissue factor [22] , antiphospholipid antibodies [23] , and hyperactivity of platelets and elevation in fibrinogen [24] . The induction of fibrinogen mRNA expression, in the acute-phase response, is mediated by IL-6 and glucocorticoids [25] . However, Anisfeld et al. [26] showed in 2005 that bile acids can also induce fibrinogen expression in human hepatoma cells via the nuclear farnesoid X receptor. This interesting finding could support the existence of a link between bile acids and the coagulation system. Whether the synthesis of other coagulation factors can be induced by bile acids remains to be proven, but as early as 1974, Lundborg and Hamberger [27] showed a general increase in hepatic synthesis of proteins in cholestatic rats. Our finding in the high FSBA group that FV, FVII, and PT increased with increasing FSBA, and were significantly correlated, could support the existence of such a mechanism in vivo.
In this study, we focused on procoagulant clotting factors as these are used for prognostic evaluation in liver disease. However, larger studies are required to verify these results and also to determine whether anticoagulant proteins such as protein S, protein C, and antithrombin are elevated in patients with high FSBA.
Conclusion
Positive correlations were found between FSBA and coagulation factors in patients with markedly elevated FSBA, although these patients had a worse outcome. The bile acids did not influence the measurement of coagulation factor levels. Consequently, coagulation factor levels may be questionable prognostic markers in pediatric chronic liver disease with severely elevated bile acids.
